Next-generation solution for genomic profiling

Oncomine Solutions on the Ion Torrent Genexus System feature a complete next-generation sequencing (NGS) testing workflow. Now every lab can go from specimen to report in a single day, providing a comprehensive genomic profile at a speed never possible before.* This allows you to deliver NGS results at the same time as other single-gene methods such as immunohistochemistry (IHC).

The hands-off, set-up-and-go workflow makes NGS accessible even if your lab is new to the technology. With the lowest sample input requirement of any NGS solution, you can successfully sequence more of the samples that come through your lab.

View webinars   Request virtual demo

Oncomine assays for the Genexus System

A46291: Oncomine Precision Assay
A39359: Oncomine Comprehensive Assay v3
A33630-A36943 Oncomine TCR Beta-LR Assay
A39359: Oncomine Myeloid Research Assay

Oncomine Precision Assay

The Oncomine Precision Assay features carefully curated biomarker content spanning 50 genes. Enhanced fusion detection provides broad coverage for the most prevalent isoforms, along with novel fusions. You have the option to profile DNA or RNA from lysate or plasma, giving you a wide range of utility. All of this is provided with a single-day turnaround time and a highly automated workflow on the Genexus System.

Download the flyer to see the complete gene list ›

Don’t let precious samples go untested

Did you know that some NGS send-out labs have test failure rates of 20% due to their high input requirement (1-4)? At that rate, one out of every five samples submitted will not pass due to lack of tissue, and many more are never submitted for testing at all. Not with Oncomine Solutions. You can experience a sequencing success rate of over 95% because we only require 10 ng of nucleic acid input. This means you can get an NGS result for most of the precious samples you have.

>95% sample access rate with Oncomine solutions

Maximize your ability to detect key biomarkers

Curated pan-cancer content

FusionSyncTM detection technology

Molecular tagging

Tissue and plasma samples

magnifying glass_DNA
  • Mutation, CNV, and fusion variant types across 50 key genes
  • Tumor suppressors, driver and resistance variants
fusion sync detection
  • Sensitive and specific—targeted isoform designs
  • Novel fusion detection
molecular tagging
  • Enhanced low-level variant detection
  • Key for liquid biopsy testing
tissue_plasma sample
  • One test, one workflow, multiple sample types
  • Maximizes the number of tumors that can be profiled

All you need to know about Oncomine Precision Assay in 30 seconds: download the infographic ›

FusionSync detection technology

Gene fusions are an increasingly important target in precision oncology. Oncomine assays are superior for both sequencing success rate and sensitivity, two critical factors for fusion detection. Even when tissue is very limited or the variants exist at low levels in the sample, you can detect key fusions by combining:

  • Targeted known fusion detection
  • Non-targeted detection of novel fusion combinations
  • Novel fusion detection

OncomineWorld 2021: A Virtual NGS Education Meeting


Free & on-demand
We recently welcomed thousands of professionals to OncomineWorld 2021 to hear from pathology labs on important topics like hot and emerging biomarker testing, genomic instability, and new user experiences with the Ion Torrent Genexus NGS System in solid and hematologic tumor clinical research. All event content is now on demand - Earn continuing education (CE) credits from dozens of NGS presentations from our 2020 and 2021 meetings, visit interactive NGS laboratories, browse our poster hall, and much more!

Access now

Three-part on-demand webinar series

Part 1: Introducing a New World of NGS: A One-Day, Hands-Free Solution to Fit Any Lab

  • Learn how the Genexus System addresses key challenges to NGS adoption
  • See the next-generation solution for genomic profiling of cancer samples
  • Hear about the experience of the first laboratory to implement this solution: IPATIMUB in Portugal

Part 2: A New World of NGS, a New Day for Your Lab

  • Understand how the new Ion Torrent Genexus System helps enable a broad spectrum of labs, even without previous expertise, to provide fast genomic profiling
  • See the future Genexus System assays pipeline
  • Hear from Sentara Molecular Pathology Laboratory about their experience

Part 3: Hear Both Sides of the Fusion Detection Story

  • Review a study that compared three different methods for fusion detection
  • Learn about FusionSync™ Detection Technology, a new method for comprehensive and sensitive gene-fusion detection and real-world data
  • Discuss the importance of detecting both novel fusions and known driver genes and partners


José Luis Costa, PhD
Andy Felton, PhD
Thermo Fisher Scientific
Wei Song, MD,
Englander Institute for Precision Medicine
Philip Jermann,
University Hospital Basel
Tabetha Sundin, PhD
Sentara Healthcare

Advancing Precision Oncology

NGS is the platform of choice for genomic profiling. The days of having to run multiple single gene tests are over. You no longer have to settle for time delays and depletion of tissue. With NGS, you can assess multiple biomarkers simultaneously in a single test for a comprehensive molecular profile, all while preserving tissue.  Visit our educational website to learn how NGS is helping advance precision oncology from research to reality.

Learn more ›

Request a quote



1. Davis W, et al. Next-Generation Sequencing in 305 Consecutive Patients: Clinical Outcomes and Management Changes. J Oncol Pract. 2019 Aug 2:JOP1900269.
2. Ready N, et al. First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. J Clin Oncol. 2019 Apr 20;37(12):992-1000.
3. Zhu J, et al. Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer. Urol Oncol. 2019 Jul 18. pii: S1078-1439(19)30244-3.
4. Heeke S, et al. Abstract 4889: Comparison of tumor mutational burden using the Ion Oncomine TML and FoundationOne assays with routine clinical FFPE tissue samples to predict durable clinical benefit in lung cancer and melanoma patients - a multivariate analysis integrating PD-L1 and CD8+ evaluation. Proceedings: AACR Annual Meeting 2019. DOI: 10.1158/1538-7445.AM2019-4889.